Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

David M Burger

Showing results (191-200 of 337) with videos related to

Pageof 34
Sort By:
Antimicrobial Agents and Chemotherapy|March 23, 2016
Inhibitory Potential of Antifungal Drugs on ATP-Binding Cassette Transporters P-Glycoprotein, MRP1 to MRP5, BCRP, and BSEPVincent J C Lempers, Jeroen J M W van den Heuvel, Frans G M Russel, et al.
Antiviral Therapy|December 3, 2003
A once-daily HAART regimen containing indinavir + ritonavir plus one or two nucleoside reverse transcriptase inhibitors (PIPO study)David M Burger, Rob E Aarnoutse, Jeanne P Dieleman, et al.
Psychopharmacology|March 11, 2015
Safety, pharmacodynamics, and pharmacokinetics of multiple oral doses of delta-9-tetrahydrocannabinol in older persons with dementiaAmir I A Ahmed, Geke A H van den Elsen, Angela Colbers, et al.
Clinical and Translational Science|February 14, 2020
Quantification of Adverse Drug Reactions Related to Drug Switches in The NetherlandsPieter J Glerum, Marc Maliepaard, Vincent de Valk, et al.
Antiviral Therapy|February 5, 2008
Relationships between drug exposure, changes in metabolic parameters and body fat in HIV-infected patients switched to a nucleoside sparing regimenReshma S Autar, Mark A Boyd, Ferdinand W M N Wit, et al.
Clinical Pharmacokinetics|April 12, 2014
Viral hepatitis C therapy: pharmacokinetic and pharmacodynamic considerationsClara T M M de Kanter, Joost P H Drenth, Joop E Arends, et al.
Topics in Antiviral Medicine|February 18, 2014
Ergotism in Thailand caused by increased access to antiretroviral drugs: a global warningAnchalee Avihingsanon, Reshmie A Ramautarsing, Gompol Suwanpimolkul, et al.
European Journal of Gastroenterology & Hepatology|August 24, 2010
Suboptimal endogenous erythropoietin response in chronic hepatitis C patients during ribavirin and PEG interferon treatmentLotte G Van Vlerken, Hanneke Van Soest, Mart P Janssen, et al.
Journal of Acquired Immune Deficiency Syndromes (1999)|October 4, 2003
Pharmacokinetics of indinavir/ritonavir (800/100 mg) in combination with efavirenz (600 mg) in HIV-1-infected subjectsMark A Boyd, Rob E Aarnoutse, Kiat Ruxrungtham, et al.
Antiviral Therapy|October 2, 2003
Administration of indinavir and low-dose ritonavir (800/100 mg twice daily) with food reduces nephrotoxic peak plasma levels of indinavirRob E Aarnoutse, Jan-Christian Wasmuth, Gerd Fätkenheuer, et al.
Pageof 34

Showing results (191-200 of 337) with videos related to

Sort By:
Pageof 34
Antimicrobial Agents and Chemotherapy|March 23, 2016
Inhibitory Potential of Antifungal Drugs on ATP-Binding Cassette Transporters P-Glycoprotein, MRP1 to MRP5, BCRP, and BSEPVincent J C Lempers, Jeroen J M W van den Heuvel, Frans G M Russel, et al.
Antiviral Therapy|December 3, 2003
A once-daily HAART regimen containing indinavir + ritonavir plus one or two nucleoside reverse transcriptase inhibitors (PIPO study)David M Burger, Rob E Aarnoutse, Jeanne P Dieleman, et al.
Psychopharmacology|March 11, 2015
Safety, pharmacodynamics, and pharmacokinetics of multiple oral doses of delta-9-tetrahydrocannabinol in older persons with dementiaAmir I A Ahmed, Geke A H van den Elsen, Angela Colbers, et al.
Clinical and Translational Science|February 14, 2020
Quantification of Adverse Drug Reactions Related to Drug Switches in The NetherlandsPieter J Glerum, Marc Maliepaard, Vincent de Valk, et al.
Antiviral Therapy|February 5, 2008
Relationships between drug exposure, changes in metabolic parameters and body fat in HIV-infected patients switched to a nucleoside sparing regimenReshma S Autar, Mark A Boyd, Ferdinand W M N Wit, et al.
Clinical Pharmacokinetics|April 12, 2014
Viral hepatitis C therapy: pharmacokinetic and pharmacodynamic considerationsClara T M M de Kanter, Joost P H Drenth, Joop E Arends, et al.
Topics in Antiviral Medicine|February 18, 2014
Ergotism in Thailand caused by increased access to antiretroviral drugs: a global warningAnchalee Avihingsanon, Reshmie A Ramautarsing, Gompol Suwanpimolkul, et al.
European Journal of Gastroenterology & Hepatology|August 24, 2010
Suboptimal endogenous erythropoietin response in chronic hepatitis C patients during ribavirin and PEG interferon treatmentLotte G Van Vlerken, Hanneke Van Soest, Mart P Janssen, et al.
Journal of Acquired Immune Deficiency Syndromes (1999)|October 4, 2003
Pharmacokinetics of indinavir/ritonavir (800/100 mg) in combination with efavirenz (600 mg) in HIV-1-infected subjectsMark A Boyd, Rob E Aarnoutse, Kiat Ruxrungtham, et al.
Antiviral Therapy|October 2, 2003
Administration of indinavir and low-dose ritonavir (800/100 mg twice daily) with food reduces nephrotoxic peak plasma levels of indinavirRob E Aarnoutse, Jan-Christian Wasmuth, Gerd Fätkenheuer, et al.
Pageof 34